证券代码：603658 证券简称：安图生物 公告编号：2023-048 二、同类产品相关情况 根据国家药品监督管理局官网数据查询信息，截至公告日，国内外同行业部 分厂家已取得上述部分类似产品的医疗器械注册证。详情请登录国家药品监督管 理局（https://www.nmpa.gov.cn/）查阅。 三、对公司的影响 上述医疗器械注册证的取得进一步丰富了公司产品菜单，不断满足市场需 求，是对公司现有检测产品的有效补充，可以逐步提高公司产品的整体竞争力， 短期内对公司的经营业绩影响较小。 四、风险提示 郑州安图生物工程股份有限公司 关于获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近日收 到河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编 | 产品名称 | 注册证编号 | 注册证 | 预期用途 | | --- | --- | --- | --- | --- | | 号 | | | 有效期 | | | | 抗中性粒细胞胞浆蛋白 | ...

Financial Performance - The company's revenue for Q3 2023 was ¥1,134,556,200.95, representing a decrease of 6.33% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥355,047,363.97, down 2.82% year-on-year[4]. - The basic earnings per share for Q3 2023 was ¥0.61, a decrease of 3.17% compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2023 was ¥3,242,497,407.54, a slight decrease from ¥3,281,481,000.43 in the same period of 2022, representing a decline of approximately 1.18%[18]. - Total operating costs for the first three quarters of 2023 were ¥2,326,702,156.56, down from ¥2,377,505,303.69 in 2022, indicating a decrease of about 2.12%[18]. - Net profit for the third quarter of 2023 was ¥915,410,745.17, compared to ¥915,428,909.15 in the same quarter of 2022, showing a marginal decrease of 0.002%[19]. - The total comprehensive income for the third quarter of 2023 was ¥915,998,287.10, slightly down from ¥916,703,080.59 in the same quarter of 2022[20]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥11,072,219,908.39, an increase of 5.73% from the end of the previous year[5]. - The company's total liabilities reached ¥2,714,260,377.35, up from ¥2,560,138,484.97, which is an increase of about 6.0%[16]. - The company's total assets and shareholders' equity as of the end of the third quarter of 2023 were ¥11,072,219,908.39 and ¥8,357,959,531.04, respectively, compared to ¥10,472,319,073.02 and ¥7,912,180,588.05 in the previous year[17]. - The company's cash and cash equivalents decreased to RMB 443,065,646.47 from RMB 1,137,621,764.53, reflecting a decline of about 61.0%[13]. - Accounts receivable increased to RMB 1,109,622,391.82 from RMB 1,052,439,134.18, showing a growth of approximately 5.4%[13]. - The company's inventory stood at RMB 748,795,765.35, slightly down from RMB 752,303,140.17, indicating a decrease of about 0.5%[15]. - Total current liabilities increased to RMB 2,271,767,026.04 from RMB 2,166,856,343.92, marking an increase of approximately 4.8%[16]. - The company reported a significant increase in other current assets, which rose to RMB 3,934,718,129.98 from RMB 3,184,609,065.62, reflecting a growth of approximately 23.5%[15]. - The company’s long-term equity investments decreased to RMB 8,195,509.00 from RMB 10,755,004.86, a decline of about 23.7%[15]. - The company’s non-current assets totaled RMB 4,691,691,677.99, an increase from RMB 4,218,771,371.55, representing a growth of approximately 11.2%[15]. - The company’s total equity remained stable at RMB 4,100,916,401.24, unchanged from the previous reporting period[16]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥951,113,025.41, reflecting a decrease of 5.69%[5]. - Cash flow from operating activities for the first three quarters of 2023 was ¥3,487,002,862.64, compared to ¥3,464,806,882.08 in the same period of 2022, indicating an increase of approximately 0.64%[21]. - Net cash flow from operating activities for Q3 2023 was ¥951,113,025.41, a decrease of 5.7% compared to ¥1,008,547,134.85 in Q3 2022[22]. - Total cash inflow from financing activities was ¥1,012,000,000.00, an increase of 26.4% from ¥801,000,000.00 in the same period last year[23]. - Cash outflow from investing activities totaled ¥1,599,897,102.58, down 43.5% from ¥2,831,898,507.03 in Q3 2022[22]. - Cash and cash equivalents at the end of Q3 2023 were ¥442,045,146.47, a decrease from ¥849,350,675.04 at the end of Q3 2022[23]. - The company received cash from other operating activities amounting to ¥96,474,518.61, down 27.6% from ¥133,234,117.54 in Q3 2022[22]. - Cash paid to employees increased to ¥852,863,771.00, up 14.2% from ¥746,670,373.16 in the previous year[22]. - Cash flow from investment activities showed a net outflow of ¥1,457,441,784.66, compared to a net outflow of ¥855,683,891.09 in Q3 2022[22]. - The company reported cash inflow from the disposal of fixed assets of ¥277,000.00, an increase from ¥200,300.00 in the same quarter last year[22]. - Cash flow from financing activities showed a net outflow of ¥191,706,034.07, compared to a net outflow of ¥75,024,124.23 in Q3 2022[23]. - The impact of exchange rate changes on cash and cash equivalents was ¥3,478,675.26, compared to ¥4,116,399.23 in Q3 2022[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,698[8]. - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 323,879,773 shares, accounting for 55.24% of the total shares[9]. Research and Development - Research and development expenses for the first three quarters of 2023 amounted to ¥461,553,959.80, an increase from ¥396,959,203.55 in the same period of 2022, reflecting a growth of approximately 16.3%[18]. - The company has not disclosed any new product developments or market expansion strategies in this report[6]. Investment Income - The company reported a decrease in investment income from joint ventures, with a loss of ¥2,554,793.87 in the third quarter of 2023 compared to a loss of ¥117,843.63 in the same quarter of 2022[19].

证券代码：603658 证券简称：安图生物 公告编号：2023-047 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理赎回 及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2. 2023 年 7 月 5 日，公司通过上海浦东发展银行使用公开发行可转换公司债 券闲置募集资金购买大额存单 2,000 万元。公司已于 2023 年 10 月 20 日赎回上述 产品，收回本金人民币 2,000 万元，累计获得利息收益人民币 21.58 万元。上述大 额存单本金和转让收益于 2023 年 10 月 20 日归还至募集资金账户。 上述大额存单存续期间可转让，公司根据募投项目建设进展情况对其进行赎回。 | 受托方名称 | 产品 | 产品名称 | 金额（万 | 实际收 益率 | 起息日 | 到期日 | 赎回金额 | 实际收 益（万 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 类型 | | 元） | | | | （万元） | | | | ...

郑州安图生物工程股份有限公司 关于控股股东自愿承诺不减持公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 证券代码：603658 证券简称：安图生物 公告编号：2023-046 公司董事会将督促控股股东严格遵守上述承诺，并按照《公司法》《证券法》 以及中国证监会、上海证券交易所相关法律法规的规定，及时履行相关信息披露 义务。 特此公告。 郑州安图生物工程股份有限公司董事会 2023 年 9 月 21 日 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近日收 到公司控股股东郑州安图实业集团股份有限公司（以下简称"安图实业"）出具的 《关于未来 6 个月内不减持安图生物股份的承诺函》，具体情况如下： 基于对公司未来发展前景的信心以及长期投资价值的认可，为维护中小投资 者利益、提振市场投资信心，公司控股股东安图实业自愿承诺：自本承诺公告日 （2023 年 9 月 22 日）起未来 6 个月内不以任何方式减持所持有的公司股份，且 在上述承诺期间内因公司送红股、转增股本、配股等原因而增加的股份，对新增 股 ...

证券代码：603658 证券简称：安图生物 公告编号：2023-045 郑州安图生物工程股份有限公司 关于召开 2023 年半年度业绩说明会的公告 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 9 月 11 日 下午 16:00-17:00 会议召开时间：2023 年 9 月 11 日（星期一）下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 9 月 4 日（星期一）至 9 月 8 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 autobio@autobio.com.cn 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证 ...

证券代码：603658 证券简称：安图生物 公告编号：2023-043 郑州安图生物工程股份有限公司持股 5%以上股东 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 Z&F INTERNATIONAL TRADING LIMITED（以下简称"Z&F"）持有 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"） 76,892,416 股股份，占本公司总股本的 13.12%，股份来源为公司首次公开 发行股票并上市前已发行的股份和通过公司权益分派资本公积转增股本取 得的股份。 减持计划的实施结果情况 公司于 2023 年 1 月 20 日在上海证券交易所网站（www.sse.com.cn） 披露《安图生物持股 5%以上股东减持股份计划公告》（公告编号：2023-008）。 公司持股 5%以上股东 Z&F 计划以竞价交易和大宗交易方式减持公司股份 合计不超过 17,588,167 股，即不超过公司股份总数的 3%。采取竞价交易方 式的，在任意连续 90 日内 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a year-on-year increase of 15%[10]. - The company's operating revenue for the first half of 2023 was approximately ¥2.11 billion, representing a 1.82% increase compared to the same period last year[14]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥545.87 million, reflecting a 2.32% increase year-over-year[14]. - The basic earnings per share for the first half of 2023 was ¥0.94, up 3.30% from ¥0.91 in the same period last year[15]. - The net profit for the first half of 2023 was CNY 555,301,480.13, compared to CNY 548,123,316.87 in the previous year, reflecting a slight increase[124]. - The total comprehensive income for the first half of 2023 was CNY 555,917,473.38, compared to CNY 548,715,232.55 in the same period of 2022[124]. - The company reported a net loss of approximately 418.94 million RMB for the first half of 2023, indicating a significant financial challenge[141]. Research and Development - Research and development expenses increased by 30% compared to the previous year, reflecting the company's commitment to innovation and new technology development[10]. - The company has a total of 1,755 R&D personnel, accounting for 31.85% of the total workforce, with 91.28% holding a bachelor's degree or higher[37]. - The company's R&D investment for the reporting period was CNY 310.91 million, accounting for 14.75% of revenue, with a total of 1,278 patents obtained, including 60 international patents[56]. - R&D investments from 2020 to 2022 were 346.37 million, 485.95 million, and 571.69 million CNY, representing 11.63%, 12.90%, and 12.87% of revenue respectively[37]. - The company has established multiple R&D platforms for various diagnostic reagents, enhancing its technological development capabilities[39]. Market Position and Strategy - The company plans to launch three new diagnostic products by the end of 2023, aiming to capture a larger market share in the in-vitro diagnostics sector[10]. - Future outlook includes a projected revenue growth of 25% for the full year 2023, driven by new product launches and market expansion efforts[10]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and expand its product offerings[10]. - The company is positioned in the in vitro diagnostic product manufacturing industry, which is experiencing rapid growth due to advancements in technology and healthcare policies[19]. - The company has established partnerships with two leading hospitals to enhance its market presence and improve product validation processes[10]. Environmental Compliance - The company reported a total wastewater discharge of 53,739.93 tons from January 1, 2023, to June 30, 2023, with a daily average COD concentration of 22.523 mg/L, and a total COD discharge of 1.2014 tons[77]. - The approved total discharge for COD is 5.49 tons/year, and for ammonia nitrogen, it is 0.85 tons/year, with no exceedance of total discharge limits reported[77]. - The company has installed a 500 m³/d wastewater treatment station to ensure compliance with discharge standards[80]. - The company has achieved ISO14001 environmental management system certification, indicating a commitment to environmental protection[85]. - The company has established a dedicated "Safety and Environmental Protection Department" to oversee environmental compliance and initiatives[85]. Shareholder and Governance - The actual controller and major shareholders have promised not to interfere with the company's management activities and to protect the company's interests[96]. - The company has committed to not seeking improper benefits from its controlling shareholder status[98]. - The company completed a share repurchase of 5,260,910 shares, accounting for 0.8973% of the total share capital, with a total payment of approximately RMB 243.27 million[106]. - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 323,904,473 shares, representing 55.25% of the total shares[108]. - The company has not reported any significant litigation or arbitration matters during the reporting period[100]. Product Development and Innovation - The company has introduced automated magnetic chemiluminescence immunoassay instruments with testing capacities of 200, 100, 180, and 600 tests per hour, gaining 153 registration certificates[41]. - The company has developed a range of quality control products, obtaining 56 medical device registration certificates and 90 national secondary standard material numbers[46]. - The company has established a POCT division to meet the diagnostic needs of grassroots medical units, focusing on products like colloidal gold and POCT chemiluminescence[52]. - The newly launched Autolas X-1 series automated laboratory line has received widespread market acclaim for its high performance and intelligence, with cumulative installations covering most provinces in China[56]. - The company continues to expand its product offerings, having registered 30 new products during the reporting period, covering various disease detection methods[56]. Financial Health and Cash Flow - The net cash flow from operating activities decreased by 5.84% to approximately ¥536.44 million compared to the previous year[14]. - The company’s cash flow from investment activities showed a significant increase in outflow, amounting to -¥943,939,973.21, a 59.40% increase compared to -¥592,176,286.25 last year[60]. - The company’s cash and cash equivalents decreased by 58.54%, from ¥1,137,621,764.53 to ¥471,621,976.22, primarily due to dividends, repayment of letters of credit, and investment in financial products[63]. - The company’s cash flow from financing activities totaled CNY 765,000,000.00, up from CNY 632,000,000.00 in the previous year, reflecting a 21% increase[130]. - The company reported a long-term investment of RMB 9,285,369.00, down from RMB 10,755,004.86 at the end of 2022[116]. Regulatory Compliance and Risks - The company faces risks from industry policy changes, which could adversely affect operations if not properly managed[71]. - The management highlighted the importance of risk management strategies in navigating potential market fluctuations and regulatory changes[10]. - The company has not faced any regulatory penalties or compliance issues during the reporting period[100]. - The company has committed to adhering to new regulatory requirements from the China Securities Regulatory Commission regarding compensation measures[96]. - The company has emphasized the importance of maintaining fair pricing in related transactions to ensure compliance with regulations[96].

证券代码：603658 证券简称：安图生物 公告编号：2023-042 郑州安图生物工程股份有限公司 2023 年上半年募集资金存放和实际使用专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所上市公司自律监管指引第1号——规范运作》等的规定，现将郑州 安图生物工程股份有限公司（以下简称："公司""本公司"）截至2023年06月30日募集 资金存放及使用情况报告如下： 根据收到的中国证券监督管理委员会出具的《关于核准郑州安图生物工程股份有 限公司非公开发行股票的批复》（证监许可[2020]2079号）核准，本公司向特定对象 非公开发行不超过43,060,289股新股。根据发行结果，公司向10名特定对象非公开发 行股票20,375,760股，每股面值1元，发行价格151.16元/股，募集资金总额为 3,079,999,881.60元，本公司主承销商招商证券股份有限公司已于2020年11月3日将扣 除相关承销保荐费用人民币26,719,9 ...

经与会董事认真审议，以记名投票表决方式一致通过以下议案： 证券代码：603658 证券简称：安图生物 公告编号：2023-040 郑州安图生物工程股份有限公司 第四届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 郑州安图生物工程股份有限公司（以下简称"安图生物"或"公司"）第四届董 事会第十一次会议的会议通知和材料于2023年8月7日以电子邮件方式发出，会议 于2023年8月17日在公司会议室以现场和通讯相结合的方式召开，会议应参加董事 9名，实际参加表决董事9名（其中独立董事张禾、李志军以通讯方式参加会议， 董事张亚循先生委托董事苗拥军先生参会）。会议由公司董事长苗拥军先生主持， 公司监事和部分高级管理人员列席了本次会议。 会议的召集和召开程序符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 1. 审议通过《关于2023年半年度报告及摘要的议案》 内容详见公司同日在上海证 ...

郑州安图生物工程股份有限公司独立董事 关于公司第四届董事会第十一次会议相关事项的独立意见 根据《公司法》《公司章程》《上海证券交易所上市公司自律监管指引第 1 号 —规范运作》等的有关规定，作为郑州安图生物工程股份有限公司（以下简称"公 司"）的独立董事，对公司第四届董事会第十一次会议审议的相关事项发表如下独 立意见： 公司编制的《安图生物 2023 年上半年募集资金存放和实际使用专项报告》 内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，公司 2023 年上半年募集资金的存放和使用情况符合中国证券监督管理委员会、上海证券交 易所关于上市公司募集资金存放和使用的相关规定，不存在违规使用募集资金的 行为，不存在因改变或变相改变募集资金投向而损害股东利益的情况。我们一致 同意该议案。 郑州安图生物工程股份有限公司 独立董事：张禾 李志军 叶忠明 2023 年 8 月 17 日 《关于 2023 年上半年募集资金存放和实际使用专项报告的议案》 ...